Telomere maintenance and DNA damage responses during lung carcinogenesis

Clinical Cancer Research

Volumn 16, Issue 11, 2010, Pages 2979-2988

  Lantuejoul, Sylvie ^a,b   Raynaud, Christophe ^c   Salameire, Dimitri ^a   Gazzeri, Sylvie ^b   Moro Sibilot, Denis ^b   Soria, Jean Charles ^d,e   Brambilla, Christian ^b   Brambilla, Elizabeth ^a,b  

^a HÔPITAL MICHALLON   (France)

^b INSERM   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; HISTONE H2AX; PROTEIN P53; RETINOBLASTOMA PROTEIN; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2;

ARTICLE; ATYPICAL ALVEOLAR HYPERPLASIA; CANCER STAGING; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; MALIGNANT TRANSFORMATION; METAPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TELOMERE;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; DISEASE PROGRESSION; DNA DAMAGE; DNA-BINDING PROTEINS; HISTONES; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; PRECANCEROUS CONDITIONS; PROTEIN-SERINE-THREONINE KINASES; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 1; TELOMERIC REPEAT BINDING PROTEIN 2; TUMOR SUPPRESSOR PROTEINS;

EID: 77953105173     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0142     Document Type: Article

References (51)

1. Travis W, Brambilla E, Muller-Hermelink HK, Harris CC, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
2. Travis W, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological Typing of Pleural Tumors. In Collaboration with L H. Sobin and Pathologists from 14 Countries. World Health Organization. International Histological Classification of Tumors. Third Edition. Berlin, Heidelberg, New York: Springer; 1999.
3. Gazdar AF. The molecular and cellular basis of human lung cancer. Anticancer Res 1994;14:261-267 (Pubitemid 24128986)
4. Auerbach O, Hammond EC, Garfinkel L. Bronchial epithelium and cigarette smoking. N Engl J Med 1979;300:1395-1396
5. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100-2110
6. Nakanishi K, Kawai T, Kumaki F, et al. Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin Cancer Res 2003;9:1105-1111 (Pubitemid 36323718)
7. Lin X, Gu J, Lu C, Spitz MR, Wu X. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res 2006;12:5720-5725
8. Xia SJ, Shammas MA, Shmookler Reis RJ. Reduced telomere length in ataxia-telangiectasia fibroblasts. Mutat Res 1996;364:1-11.
9. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-198
10. De Boeck G, Forsyth RG, Praet M, Hogendoorn PC. Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol 2009;217:327-344
11. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A 1994;91:5124-5128
12. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444:633-637
13. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyperreplication. Nature 2006;444:638-642
14. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008;319:1352-1355
15. Salon C, Eymin B, Micheau O, et al. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP (short). Cell Death Differ 2006;13:260-272
16. Tanaka T, Huang X, Jorgensen E, et al. ATM activation accompanies histone H2AX phosphorylation in A549 cells upon exposure to tobacco smoke. BMC Cell Biol 2007;8:26.
17. Eymin B, Claverie P, Salon C, et al. p14ARF activates a Tip60- dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 2006;26:4339-4350
18. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-913 (Pubitemid 40559004)
19. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-870
20. Nuciforo PG, Luise C, Capra M, Pelosi G, d'Adda di Fagagna F. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 2007;28: 2082-2088
21. Raynaud CM, Jang SJ, Nuciforo P, et al. Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Ann Oncol 2008;19:1875-1881
22. Lantuejoul S, Soria JC, Morat L, et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res 2005;11:2074-2082
23. Meeker AK, Hicks JL, Platz EA, et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 2002;62:6405-6409
24. Lantuejoul S, Salon C, Soria JC, Brambilla E. Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer 2007;120:1835-1841
25. Frias C, Garcia-Aranda C, De Juan C, et al. Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer 2008;60:416-425
26. Smogorzewska A, van Steensel B, Bianchi A, et al. Control of human telomere length by TRF1 and TRF2. Mol Cell Biol 2000;20:1659-1668
27. Martinez P, Thanasoula M, Munoz P, et al. Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev 2009;23:2060-2075
28. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997;385:740-743
29. Smogorzewska A, de Lange T. Regulation of telomerase by telomeric proteins. Annu Rev Biochem 2004;73:177-208.
30. Hsu CP, Lee LW, Shai SE, Chen CY. Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus. World J Gastroenterol 2005;11:6941-6947 (Pubitemid 43126051)
31. Hsu CP, Ko JL, Shai SE, Lee LW. Modulation of telomere shelterin by TRF1 [corrected] and TRF2 interactswith telomerase tomaintain the telomere length in non-small cell lung cancer. Lung Cancer 2007;58:310-316
32. Yamada M, Tsuji N, Nakamura M, et al. Down-regulation of TRF1, TRF2 and TIN2 genes is important to maintain telomeric DNA for gastric cancers. Anticancer Res 2002;22:3303-3307
33. Matsutani N, Yokozaki H, Tahara E, et al. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int J Oncol 2001;19:507-512
34. Garcia-Aranda C, de Juan C, Diaz-Lopez A, et al. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer 2006;106:541-551
35. Raynaud CM, Hernandez J, Llorca FP, et al. DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. Am J Clin Oncol 2009. Epub ahead of print.
36. Fan C, Quan R, Feng X, et al. ATM activation is accompanied with earlier stages of prostate tumorigenesis. Biochim Biophys Acta 2006; 1763:1090-1097
37. Tort F, Bartkova J, Sehested M, Orntoft T, Lukas J, Bartek J. Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res 2006;66:10258-10263
38. Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles "heal" of lung cancers? Trends Mol Med 2004;10:481-486
39. Tang X, Varella-Garcia M, Xavier AC, et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res 2008;1:192-200.
40. Tanaka H, Yanagisawa K, Shinjo K, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007;67:6007-6011
41. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 2008;68: 2106-2111
42. Soh J, Toyooka S, Ichihara S, et al. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol 2008;3:340-347
43. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60: 1949-1960 (Pubitemid 30207657)
44. Boehrer S, Ades L, Tajeddine N, et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 2009;28:2205-2218
45. Grosjean-Raillard J, Tailler M, Ades L, et al. ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2009;28:1099-1109
46. Bartek J, Lukas J, Bartkova J. DNA damage response as an anticancer barrier: damage threshold and the concept of "conditional haploinsufficiency". Cell Cycle 2007;6:2344-2347
47. Tanaka H, Mendonca MS, Bradshaw PS, et al. DNA damage-induced phosphorylation of the human telomere-associated protein TRF2. Proc Natl Acad Sci U S A 2005;102:15539-15544
48. Celli GB, de Lange T. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol 2005;7:712-718
49. Dimitrova N, de Lange T. Cell cycle dependent role of MRN at dysfunctional telomeres: ATM signaling-dependent induction of NHEJ in G1 and resection-mediated inhibition of NHEJ in G2. Mol Cell Biol 2009;29:5552-5563
50. Karlseder J, Hoke K, Mirzoeva OK, et al. The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-dependent DNA damage response. PLoS Biol 2004;2:E240.
51. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004;4:216-225 (Pubitemid 38337501)